Abstract 219P
Background
Tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor(ICI)had demonstrated efficacy as first-line therapy for mRCC patients(pts)in clinical trials. However, data on real-world outcomes were limited. Our study aimed to evaluate the effectiveness of tislelizumab plus TKI in pts with mRCC.
Methods
Demographic and clinicopathological data of pts with mRCC between July 2019 and November 2022 were retrospectively collected from Sun Yat-sen University Cancer Center. All pts received first-line treatment with TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus TKI therapy (combination group,mainly plus axitinib). TKI group who failed first-line therapy received tislelizumab plus TKI as second-line regimen. Combination group who failed first-line therapy received TKI or ICI plus TKI as second-line regimen. Outcomes including the objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were calculated.
Results
Totally 136 pts were analyzed, with a median age of 57 (17-81) years. 72.1% were male, 71.3% had clear cell RCC, 78.8% had an IMDC intermediate/poor-risk disease, 62.5% had metastatic number≥2, metastatic organs included lung (47.1%), bone (27.9%), liver (13.2%) and brain (5.1%). The median follow-up was 26.4 (23.1-29.6) months. The combination group (n=61) had a significantly longer PFS compared with the TKI group (n=75) (median PFS (95% CI): 17.4 (13.9-20.9) vs 6.2 (5.5-6.9) months, P<0.001). Similarly, the PFS2 was longer in the combination group (median PFS2 (95% CI): 23.5 (7.7-39.3) vs 14.7 (11.1-18.3) months, P=0.011). Besides, ORR was remarkably improved in the combination group (44.3% vs 18.7%, P=0.001). Median OS was not reached for combination group and 42.9 months for TKI group (p = 0.081).
Conclusions
Our data demonstrated effectiveness of tislelizumab plus TKI as first-line treatment for mRCC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract